Do omega‑3 fatty acids increase the risk of arrhythmia, such as atrial fibrillation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Omega-3 Fatty Acids and Arrhythmia Risk

Yes, omega-3 fatty acids can increase the risk of atrial fibrillation (AF), particularly at high doses (>1500 mg/day) in patients with established cardiovascular disease, but the absolute risk increase is modest and dose-dependent.

The Evidence on Atrial Fibrillation

The most recent and comprehensive meta-analysis 1 of 35 randomized controlled trials (n=114,592) demonstrates a clear dose-response relationship:

  • High-dose omega-3 (>1500 mg/day) in high cardiovascular risk patients: Significantly increased AF risk with odds ratio 1.43 (95% CI 1.14-1.79), representing an absolute risk increase of only 0.8%
  • Low-dose omega-3 (≤1500 mg/day): No statistically significant increase in AF risk, even in high-risk populations (OR 1.07)
  • Low cardiovascular risk patients: No significant AF risk at any dose

A 2021 meta-analysis 2 of 8 large cardiovascular outcome trials (n=83,112) corroborates these findings, showing overall increased AF risk (RR 1.24,95% CI 1.11-1.38), with stronger associations at higher doses (>1g daily: RR 1.51 vs ≤1g daily: RR 1.12).

The Mechanism: A Vagally-Mediated Effect

The relationship between omega-3 and AF appears biphasic and mediated by vagal tone 3:

  • Dietary doses (~650 mg/day): Associated with 12% AF risk reduction in observational studies
  • Pharmaceutical doses (1800-4000 mg/day): Increase AF risk by ~50%
  • Mechanism: Low-level vagal stimulation from dietary omega-3 decreases AF risk, while high-level vagal stimulation from pharmaceutical doses increases AF risk

This explains why observational studies of dietary fish consumption generally show protective effects, while high-dose supplementation trials show harm.

Ventricular Arrhythmias: Mixed Evidence

For ventricular arrhythmias, the evidence from 2007 guidelines 4 shows conflicting results in ICD patients:

  • Raitt trial: Found unexpected increased risk of recurrent VT/VF in fish oil group (66% vs 43%, P<0.007) among patients whose qualifying arrhythmia was VT
  • FAAT trial: Showed trend toward benefit (28% risk reduction, P=0.057)
  • SOFA trial: No significant difference (30% vs 33%, P=0.33)

The disparate results likely relate to baseline omega-3 levels and dosing differences, making definitive conclusions difficult.

Clinical Recommendations

For patients with established cardiovascular disease:

  • Avoid high-dose omega-3 supplementation (>1500 mg/day) due to increased AF risk
  • If omega-3 therapy is indicated for other reasons, use ≤1g daily to minimize AF risk
  • Monitor for new-onset AF, particularly in the first year of treatment

For patients at low cardiovascular risk:

  • Omega-3 supplementation does not appear to increase AF risk at any dose studied

For ICD patients with history of ventricular arrhythmias:

  • Exercise caution with omega-3 supplementation given conflicting evidence 4
  • If used, consider lower doses and close monitoring

For dietary omega-3 from fish:

  • Dietary consumption (typically <1g/day) appears safe and may be protective 3
  • The 2-3 servings of fatty fish per week recommended by guidelines does not increase AF risk

Important Caveats

  • The absolute risk increase for AF with high-dose omega-3 is small (0.8%) but statistically significant 1
  • No increased stroke risk has been demonstrated despite increased AF 2
  • Short-term use (<4 weeks) of omega-3, such as in parenteral nutrition, is unlikely to increase AF risk 5
  • Plant-based omega-3 (ALA) may actually reduce AF risk in those with low marine omega-3 intake 6

The key clinical takeaway: Dose matters profoundly. Dietary omega-3 from fish is safe and potentially beneficial, while pharmaceutical high-dose supplementation (>1500 mg/day) increases AF risk in cardiovascular disease patients and should be avoided unless benefits clearly outweigh this risk.

References

Related Questions

In a patient with well‑controlled atrial fibrillation, does omega‑3 (EPA/DHA) fish‑oil supplementation increase the risk of AF recurrence or pose additional danger?
What is the relationship between Lovaza (omega-3 acid ethyl esters) and atrial fibrillation (afib)?
Is fish‑oil supplementation safe for preventing or treating cardiac arrhythmias, and what is the recommended safe dose of EPA/DHA?
In patients with atrial flutter, when should anticoagulation be initiated and which anticoagulant agents and dosing are recommended based on CHA₂DS₂‑VASc score, renal function, and other risk factors?
What are the diagnostic criteria for acute liver failure?
What is the appropriate management for an insulin‑dependent type 2 diabetic patient with a bicarbonate of 20 mEq/L, an anion gap of 23, blood glucose of 587 mg/dL, pH of 7.35, and beta‑hydroxybutyrate of 4.43 mmol/L?
Is it safe to administer subcutaneous heparin to a patient with a low platelet count?
Should I order C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for a patient with splenomegaly?
Can clonidine be administered sublingually for severe hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.